Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.

Date publication

janvier 2017

Journal

Alimentary pharmacology & therapeutics

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Colombel JF, Jharap B, Sandborn WJ, Feagan B, Peyrin-Biroulet L, Eichner SF, Robinson AM, Mostafa NM, Zhou Q, Thakkar RB

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27883215

Résumé

Adalimumab is approved for use in patients with moderate to severe Crohn's disease (CD) or ulcerative colitis (UC) who have not achieved disease control with conventional therapies including corticosteroids and/or immunomodulators (IMM).

Mots clés

Adalimumab, administration & dosage, Adult, Anti-Inflammatory Agents, administration & dosage, Colitis, Ulcerative, blood, Crohn Disease, blood, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunologic Factors, administration & dosage, Male, Middle Aged, Remission Induction, methods, Treatment Failure, Treatment Outcome

Référence

Aliment. Pharmacol. Ther.. 2017 01;45(1):50-62